Malignant phyllodes tumor of the prostate: Retrospective review of specimens obtained by sequential transurethral resection

Watanabe, Masatoshi; Yumura, Yasushi; Kato, H; Imai, Hiroshi; Nakano, Hiroshi; Araki, Tomio; Shiraishi, Taizo

doi:10.1046/j.1440-1827.2002.01417.x

Cited by 28 publications

(33 citation statements)

References 18 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies 1,4 showed that prostatic STUMP typically express progesterone receptors/CD34, and focally express or do not express desmin. Although CD34 was considered as a useful marker of prostatic STUMP and PSS, there have been some reports 7,9 which demonstrated prostatic STUMP with negative immunohistochemical staining for CD34, similar with the findings in our patient. It should be noted that the results of immunohistochemical staining in stromal tumor of the prostate are ancillary and the most important criteria for diagnosis is the morphology by routine Hematoxylin and Eosin stain, as Hansel et al 10 emphasized.…”

Section: Discussionsupporting

confidence: 90%

“…Some cases showed invasion to contiguous organs. In a minority of the cases, prostatic STUMP metastasizes to the lung and bone, and transforms to malignant PSS 1,[3][4][5][6][7] . Intriguingly, by Gaudin's classification, whereas the previous cases are mostly phyllodes tumor in type, the current case is pattern two of prostatic STUMP which spreads to right seminal vesicle and both lungs.…”

Section: Discussionmentioning

confidence: 99%

“…The neoplastic nature of prostatic STUMP remains controversial as the incidence is relatively rare and results of long term follow-up have not been established. However, there have been a few reports of high recurrence, spreading to contiguous organs, and metastasis [1][2][3][4][5][6][7][8] . We describe a case of prostatic STUMP, presenting with multiple lung metastasis found incidentally on chest X-ray.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prostatic Stromal Tumor of Uncertain Malignant Potential (STUMP) Presenting with Multiple Lung Metastasis

Lee

Kim

et al. 2010

Tuberc Respir Dis

View full text Add to dashboard Cite

We report the case of a 68-year-old man with a stromal tumor of uncertain malignant potential (STUMP), which had metastasized to the lung. The patient complained of an enlarged mass in the anterior chest. Chest computed tomography (CT) showed a sternal abscess with multiple nodules in both lungs. A thoracoscopic lung biopsy of the nodules and incision/drainage of the sternal mass were performed simultaneously. CT of the pelvis revealed an enlarged prostate with irregular cystic lesions in the pelvis. Prostate biopsy was done and demonstrated hypercellular stroma with minimal cytological atypia, a distinct pattern of STUMP. The sternal abscess proved to be tuberculosis and the lung lesion was consistent with STUMP, which had spread from the prostate. However, to our knowledge, the tuberculous abscess might not be assoicated with STUMP in the lung. The patient refused surgical prostatectomy and was discharged with anti-tuberculosis medication. On one-year follow up, the patient had no evidence of disease progression.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prostatic Stromal Tumor of Uncertain Malignant Potential (STUMP) Presenting with Multiple Lung Metastasis

Lee

Kim

et al. 2010

Tuberc Respir Dis

View full text Add to dashboard Cite

show abstract

“…Unquestionably, the potential for sarcomatous transformation, recurrence, and infiltrative growth exists, but the frequency of these changes and their prognostic significance is unclear. [3][4][5][6][7] Little is known about the genetic abnormalities in this tumor. Oncogene activation and tumor suppressor gene inactivation are important mechanisms in the genesis, propagation, and spread of most cancers, but the role of these processes in phyllodes tumor has not been previously explored.…”

mentioning

confidence: 99%

Molecular Genetic Evidence for Different Clonal Origins of Epithelial and Stromal Components of Phyllodes Tumor of the Prostate

McCarthy

Zhang

Bostwick

et al. 2004

The American Journal of Pathology

View full text Add to dashboard Cite

Phyllodes tumor of the prostate is a rare neoplasm, composed of epithelium-lined cysts and channels embedded in a variably cellular stroma. The pathogenetic relationship of the epithelium and stroma is unknown and whether each is a clonal neoplastic element is uncertain. We studied the clonality of phyllodes tumors from six patients who underwent either enucleation or transurethral resection as their initial treatment. This was followed by total prostatectomy in three of the patients. Laser-assisted microdissection was performed to extract epithelial and stromal components of phyllodes tumor from formalin-fixed, paraffinembedded tissue. Polymerase chain reaction was used to amplify genomic DNA at specific loci on chromosome 7q31 (D7S522), 8p21.3-q11.1 (D8S133, D8S137), 8p22 (D8S261), 10q23 (D10S168, D10S571), 17p13 (TP53), 16q23.2 (D16S507), 12q11-12 (D12S264), 17q (D17S855), 18p11.22-p11 (D18S53), and 22q11.2 (D22S264). In each tumor, stroma and epithelium were analyzed separately. Gel electrophoresis with autoradiography was used to detect loss of heterozygosity. All tumors showed allelic loss in one or more loci of both the epithelial and stromal components. The frequency of allelic loss in the epithelial component was 2 of 5 (40%) at D7S522, 2 of 6 (33%) at D8S133, 1 of 5 (20%) at D8S137, 3 of 6 (50%) at D8S261, 4 of 4 (100%) at D10S168, 4 of 6 (67%) at TP53, 2 of 6 (33%) at D10S571, 6 of 6 (100%) at D16S507, 1 of 5 (20%) at D12S264, 1 of 6 (17%) at D17S855, 2 of 6 (33%) at D18S53, and 2 of 5 (40%) at D22S264. The frequency of allelic loss in the stromal component was 2 of 5 (40%) at D7S522, 1 of 6 (17%) at D8S133, 2 of 5 (40%) at D8S137, 3 of 6 (50%) at Phyllodes tumor of the prostate is a rare neoplasm with poorly understood pathogenesis. Histologically, it resembles phyllodes tumor of the breast with hyperplastic epithelium-lined cysts and channels embedded in a variably cellular stroma.1,2 A variety of terms have been used to describe these lesions, including phyllodes type of atypical hyperplasia, cystosarcoma phyllodes, and prostatic cystic epithelial-stromal tumor.

show abstract

“…Correct markers for gliomas are present, including invasive cell growth into the skin layer, necrotic areas with pseudopalisading, and poorly formed blood vessels [142].…”

Section: Discussionmentioning

confidence: 99%

Drug encapsulated aerosolized microspheres as a biodegradable, intelligent glioma therapy

Floyd

Galperin

Ratner

2015

J Biomedical Materials Res

View full text Add to dashboard Cite

Departments of Bioengineering and Chemical EngineeringThe grim prognosis for patients diagnosed with malignant gliomas necessitates the development of new therapeutic strategies for localized and sustained drug delivery to combat tumor drug resistance and regrowth. Here we introduced the novel formulation of drug encapsulated aerosolized microspheres as a biodegradable, intelligent glioma therapy (DREAM BIG Therapy) that is applied post-resection. DREAM BIG Therapy consists of three types of microspheres [poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and poly(ε-caprolactone) (PCL)] containing various encapsulated chemotherapeutics, suspended in a degradable, aqueous poly(Nisopropylacrylamide) (PNIPAM) solution. The thermoresponsive PNIPAM solution is capable of suspending drug encapsulated microspheres at room temperature which can be "sprayed on" the post-surgical site. The physiological temperature of the treatment site (37°C) would cause PNIPAM solution to solidify and form an adherent gel layer with entrapped microspheres, providing intimate contact with remaining tumor cells. Over time, PLGA (rapid degradation), PLA (medium speed degradation), and then PCL (slow degradation) microspheres would break iv down, releasing their drug payloads in a sequential, multi-drug release directly to the tumor site, addressing cancerous regrowth and tumor drug resistance. This dissertation will address the development of DREAM BIG Therapy, from microsphere formulation to pilot in vivo studies.Initial work focused on developing blank and drug encapsulated microspheres using emulsion techniques. Preliminary studies utilized rhodamine B as a model drug for encapsulation in PLGA, PLA, and PCL particles and optimized formulation parameters to achieve a high encapsulation. Then, gefitinib, IgG, and lomustine were encapsulated in PLGA, PLA, and PCL microspheres, respectively, achieving encapsulation efficiencies greater than 80% and drug loadings greater than 0.3%. The in vitro release of gefitinib and IgG were also studied. Gefitinib released from PLGA microspheres over 40 days while the release of IgG from PLA microspheres was slower, over a year long period.The microsphere-PNIPAM system was tested for aerosolized application ex vivo. The aqueous PNIPAM solution suspended the microspheres and was aerosolized before phase transitioning to an adherent gel layer on the tissue, entrapping the microspheres on the tissue surface. Finally, when tested in vivo, the gefitinib encapsulated PLGA microspheres entrapped in PNIPAM slowed the tumor volume growth of a subcutaneous C6 glioma in comparison to blank PLGA microspheres entrapped in PNIPAM. Overall, this research confirms the potential of DREAM BIG therapy for future use with multiple chemotherapeutics and microsphere types to combat gliomas at a localized site.v

show abstract

Malignant phyllodes tumor of the prostate: Retrospective review of specimens obtained by sequential transurethral resection

Cited by 28 publications

References 18 publications

Prostatic Stromal Tumor of Uncertain Malignant Potential (STUMP) Presenting with Multiple Lung Metastasis

Prostatic Stromal Tumor of Uncertain Malignant Potential (STUMP) Presenting with Multiple Lung Metastasis

Molecular Genetic Evidence for Different Clonal Origins of Epithelial and Stromal Components of Phyllodes Tumor of the Prostate

Drug encapsulated aerosolized microspheres as a biodegradable, intelligent glioma therapy

Contact Info

Product

Resources

About